Journal
PAIN PRACTICE
Volume 16, Issue 2, Pages 175-182Publisher
WILEY
DOI: 10.1111/papr.12342
Keywords
local anesthetic; nerve growth factor; NGF; pain; tropomyosin receptor kinase; protein kinase; TrkA; anti-NGF antibody; tanezumab; review
Categories
Funding
- Grants-in-Aid for Scientific Research [26462375] Funding Source: KAKEN
Ask authors/readers for more resources
Nerve growth factor (NGF) was first discovered approximately 60years ago by Rita Levi-Montalcini as a protein that induces the growth of nerves. It is now known that NGF is also associated with Alzheimer's disease and intractable pain, and hence, it, along with its high-affinity receptor, tropomyosin receptor kinase (Trk) A, is considered to be 1 of the new targets for therapies being developed to treat these diseases. Anti-NGF antibody and TrkA inhibitors are known drugs that suppress NGF/TrkA signaling, and many drugs of these classes have been developed thus far. Interestingly, local anesthetics also possess TrkA inhibitory effects. This manuscript describes the development of an analgesic that suppresses NGF/TrkA signaling, which is anticipated to be 1 of the new methods to treat intractable pain.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available